Nevro1™ Proven to Immediately Transfix
Sacroiliac (SI) Joint to Allow for Long-term SI Joint
Fusion
REDWOOD
CITY, Calif., Feb. 28,
2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced that the U.S. Food and Drug Administration (FDA) cleared
its sacroiliac joint fusion device, which will be marketed as
Nevro1, without the need to include the screw ("NevroFix™").
Nevro1, an integrated transfixing technology, is proven to
immediately transfix the SI joint to allow the opportunity for
long-term fusion. Self-contained, deployable titanium anchors
transfix the sacrum and ilium to enhance axial and rotational
stability of the joint. In addition, Nevro's proprietary
instrumentation allows for optimal intra-articular SI joint
preparation which is critical to achieve joint fusion. Nevro1 comes
with 3D-printed, bone-growth enhancing technology which helps
promote bone cell growth and, as a result, fusion.
"Nevro1 as a standalone device represents the most significant
advancement in SI fusion in years. In my experience, it is the
safest and most efficient and effective true fusion implant
available," said Gregory Bailey,
M.D., an orthopedic surgeon in State
College, Pennsylvania.
"Nevro1 will be our flagship SI joint fusion product as there is
no other device like it on the market," said Kevin Thornal, Nevro's CEO and president. "We
now offer one of the most comprehensive portfolios of products in
the SI joint space, and we can meet the preferences of different
physicians and varying patient needs – ultimately helping to
improve health outcomes and quality of life for patients."
This is the first regulatory clearance since Nevro acquired
Vyrsa™ Technologies, with its suite of innovative products that
provide minimally invasive treatment options for patients suffering
from chronic SI joint pain, in November
2023. The company noted that the clearance was originally
received by Camber Spine and will be transferred to Nevro for
marketing and distribution.
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes the Senza® SCS system and
support services for the treatment of chronic pain of the trunk and
limb and painful diabetic neuropathy.
Nevro recently added a minimally invasive treatment option for
patients suffering from chronic sacroiliac joint ("SI joint") pain
and now provides the most comprehensive portfolio of products in
the SI joint fusion space, designed to meet the preferences of
physicians and varying patient needs in order to improve outcomes
and quality of life for patients.
Senza®, Senza II®, Senza
Omnia®, and HFX iQ™ are the only SCS systems that
deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support
services provide every patient with HFX Coach™ support throughout
their pain relief journey and every physician with HFX Cloud™
insights for enhanced patient and practice management.
Senza, Senza II, Senza Omnia , Omnia, 10 kHz Therapy, HFX,
HFX iQ, HFX Coach, HFX Cloud, NevroFix, NevroPro, Nevro1, Nevro,
and the NEVRO logo are trademarks or registered trademarks of Nevro
Corp. Patents covering Senza HFX iQ and other Nevro products are
listed at Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, X,
Facebook, and Instagram.
Investors and Media:
Angie McCabe
Vice President, Investor Relations & Corporate
Communications
angeline.mccabe@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-receives-fda-510k-clearance-to-use-si-fixation-system-without-need-to-include-lateral-screw-302074776.html
SOURCE Nevro Corp.